Accepted Manuscript

Title: Cilostazol, a PDE3 inhibitor, activates proteasome proteolysis and attenuates tauopathy and cognitive decline

Author: Ari W. Schaler, Natura Myeku

PII: S1931-5244(17)30313-4
DOI: https://doi.org/10.1016/j.trsl.2017.11.004
Reference: TRSL 1203

To appear in: *Translational Research*

Received date: 9-5-2017
Revised date: 25-10-2017
Accepted date: 16-11-2017

Please cite this article as: Ari W. Schaler, Natura Myeku, Cilostazol, a PDE3 inhibitor, activates proteasome proteolysis and attenuates tauopathy and cognitive decline, *Translational Research* (2017), https://doi.org/10.1016/j.trsl.2017.11.004.

, a PDE3 inhibitor, activates proteasome proteolysis and attenuates tauopathy and cognitive decline

Ari W. Schaler[1] and Natura Myeku[1*]

[1] Department of Pathology and Cell Biology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA.

***Corresponding author:**

Natura Myeku, Ph.D.

Assistant Professor of Pathology and Cell Biology

Department of Pathology and Cell Biology,

Taub Institute for Research on Alzheimer's Disease and the Aging Brain

Columbia University Medical Center

168th West, P&S 12-440. New York, NY, 10032.

Tel: (212) 305-8973

nm2631@cumc.columbia.edu

Running head:

PDE inhibitors as proteasome activators

Abbreviations

AD = Alzheimer's disease; CBD = Corticobasal degeneration; FTD = Frontotemporal degeneration; FDA = Food and drug administration; GST-UBL= glutathione-S-transferase–ubiquitin-like domain; HD = Huntington's disease; MWM = Morris water maze; MCI = mild cognitive impairment; PDEI = phosphodiesterase inhibitor; PKA = protein kinase A; PSP = Progressive Supranuclear palsy; UPS = Ubiquitin proteasome system.